Basilea Pharmaceutica AG
SIX:BSLN
Basilea Pharmaceutica AG
SIX:BSLN
Price:
42.85 CHF
5.28%
Market Closed
Updated:
May 9, 2024
Basilea Pharmaceutica AG
Net Income (Common)
|
Basilea Pharmaceutica AG
Net Income (Common) Peer Comparison
Comparables:
ADCT
ACIU
CRSP
IDIA
KURN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Net Income (Common)
CHf10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Net Income (Common)
-$240.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Net Income (Common)
-CHf54.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Net Income (Common)
-$153.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Net Income (Common)
-CHf827.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-125%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Net Income (Common)
-CHf13.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
See Also
What is Basilea Pharmaceutica AG's Net Income (Common)?
Net Income (Common)
10.5m
CHF
10.5m
CHF
Based on the financial report for Dec 31, 2023, Basilea Pharmaceutica AG's Net Income (Common) amounts to 10.5m CHF.
What is Basilea Pharmaceutica AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
-14%
-14%
Over the last year, the Net Income (Common) growth was -14%.
You don't have any saved screeners yet
